Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom
Go back to Madrigal Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom| (NASDAQ: MDGL) | Delayed: 497.71 +4.09 (0.83%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $493.62 | 52 Week High | $18.24 | |||
| Open | $497.08 | 52 Week Low | $6.60 | |||
| Day High | $504.06 | P/E | N/A | |||
| Day Low | $478.71 | EPS | $0.00 | |||
| Volume | 166,177 | |||||



